Physician profile
William Lear
NPI 1558553115
$1,458.64
in general payments reported to CMS, 2019-2025
19 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.03 · 2020: $17.11 · 2021: $78.84 · 2022: $205 · 2023: $489 · 2024: $90.42 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $290.96 | 2022-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $205.68 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $190.29 | 2023-2025 | Dupixent |
| Medline Industries Lp | $152.87 | 2023 | |
| Novartis Pharmaceuticals Corporation | $95.14 | 2021-2022 | |
| Abbvie INC. | $87.62 | 2020-2025 | |
| Genzyme Corporation | $85.80 | 2022-2025 | |
| Conmed Corporation | $57.40 | 2019 | |
| Incyte Corporation | $45.03 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $36.27 | 2022-2023 | Odomzo, Blu-U |
| Ucb, INC. | $34.49 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.13 | 2023 | Spevigo |
| Pfizer INC. | $30.75 | 2025 | |
| Smith+Nephew, INC. | $26.96 | 2023 | Grafix Pl |
| Leo Pharma INC. | $26.15 | 2025 | Anzupgo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.49 | 2023 | Sotyktu |
| Biofrontera INC. | $15.86 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Pharming Healthcare, INC. | $15.43 | 2025 | Ruconest |
| Arcutis Biotherapeutics, INC. | $13.32 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.